DRKS00031864已完成不适用
Epileptology and NeuroPalliativeCare: Seizures in End of Life - EPIxPA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •physicians specialized in palliative care
排除标准
- •I) No board examination in palliative care.
- •Less than 1 year of practical experience in palliative care.
研究者
相似试验
已完成
3 期
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes post Worsening Heart FailureNL-OMON50219exicon Pharmaceuticals, Inc.65
进行中（未招募）
1 期
Effect of Efpeglenatide on Cardiovascular OutcomesType 2 diabetes mellitusMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-002954-35-FIsanofi-aventis recherche & développement5,000
进行中（未招募）
1 期
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskType 2 diabetes mellitusChronic kidney diseaseMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2017-002644-32-NOSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT16,154
进行中（未招募）
1 期
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-006165-11-DEJanssen-Cilag International NV350
撤回
2 期
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple-dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)NL-OMON53971Bristol-Myers Squibb6